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Proliferative diabetic retinopathy (PDR) can cause se-
vere visual loss due to the development of neovascular 
glaucoma (NVG) [1]. NVG in PDR often appears as a re-
fractory condition that is not well controlled by any medi-
cal treatment. Glaucoma drainage implants have been used 
in the treatment of refractory glaucoma in PDR patients. 
Typically, the tube is placed in the anterior chamber and 
acts to shunt aqueous fluid to an equatorial implant [2,3]. 
NVG patients with PDR often subsequently experience 
vitreous hemorrhage or vitreous opacity, which interferes 
with conventional panretinal photocoagulation and may 
require vitrectomy. Moreover, the anterior chamber may 
not be the proper site for tube implantation in cases such as 
advanced glaucoma with secondary angle closure or angle 
neovascularization, corneal diseases, and other anterior 
chamber abnormalities. In such cases, the implant can be 
placed through pars plana combined with vitrectomy [4-7]. 
Several studies have showed pars plana vitrectomy with 
implantation of a drainage tube into the vitreous cavity 
achieved a success rate comparable to the success rate of 
an anterior chamber implant in refractory NVG [8-12]. 
Recently, 23 or 25-gauge sutureless vitrectomy has be-
come more popular than 20-gauge vitrectomy. The small 
gauge vitrectomy has potential advantages over traditional 
20-gauge pars plana vitrectomy, which includes improved 
healing time, increased postoperative comfort and dimin-
ished disturbance of the conjunctiva particularly with re-
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Purpose: To evaluate the efficacy and safety of a pars plana Ahmed valve implantation combined with 
23-gauge sutureless vitrectomy in the treatment of patients with medically uncontrolled neovascular glaucoma 
(NVG) in proliferative diabetic retinopathy (PDR).
Methods: The authors retrospectively reviewed the records of 11 consecutive patients with refractory NVG in 
PDR who underwent a 23-gauge sutureless vitrectomy combined with pars plana placement of an Ahmed 
valve implant. Control of intraocular pressure (IOP), pre- and postoperative best-corrected visual acuity and 
the development of intra- and postoperative complications were evaluated during the follow-up.
Results: The mean follow-up was 12.2 months (range, 8 to 25 months). Mean preoperative IOP was 35.9 ± 6.3 
mmHg and mean postoperative IOP at the last visit was 13.3 ± 3.2 mmHg. Control of IOP (8 to 18 mmHg) was 
achieved in all patients, but 91% (10 of 11 patients) needed antiglaucoma medication (mean number of medica-
tions, 1.2 ± 0.6). Postoperative visual acuity improved in 11 eyes, and the logarithmically to the minimum angle 
of resolution mean visual acuity in these eyes improved from 1.67 ± 0.61 to 0.96 ± 0.67. The complications that 
occurred were transient hypotony in one case, transitory hypertension in two cases, and postoperative vitre-
ous hemorrhage which spontaneously cleared in two cases.
Conclusions: We suggest the combination of 23-gauge pars plana vitrectomy and Ahmed valve implantation is 
safe and effective in PDR patients with refractory NVG.
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gard to trabeculectomy sites [13].
The purpose of this retrospective case series was to 
report on the outcome of pars plana Ahmed valve implan-
tation combined with 23-gauge pars plana vitrectomy in 
patients with uncontrolled NVG in PDR. 
Materials and Methods
The study was approved by the institutional review 
board of Gil Medical Center and adhered to the Declara-
tion of Helsinki. The charts of PDR patients who had un-
controlled neovascular glaucoma which was unresponsive 
to medical treatment and underwent 23-gauge sutureless 
vitrectomy combined with Ahmed valve implantation by 
the same vitereoretinal surgeon (DYL) between March 1, 
2008, and January 31, 2010, were reviewed retrospectively. 
Eleven patients met the criteria of this study (NVG with an 
intraocular pressure [IOP] ≥30 mmHg despite maximum 
tolerated oral and topical antiglaucoma medical therapy, 
dense vitreous opacity or vitreous hemorrhage and un-
derlying retinal pathology [diabetic retinopathy]). Data 
collected included demographic information, indications 
for combined procedure, complications, preoperative and 
postoperative best-corrected visual acuity, and IOP (which 
was measured with a Goldmann applanation tonometer). 
Following retrobulbar anesthesia, a fornix-based con-
junctival peritomy with relaxing incisions was made in 
either the superotemporal or superonasal quadrants, and 
the adjacent extraocular rectus muscles were isolated with 
a muscle hook. A Model FP7 Ahmed glaucoma valve 
(NewWorld Medical Inc., Rancho Cucamonga, CA, USA) 
was used for six patients and a model FP8 (NewWorld 
Medical Inc.) for five patients. Patency of the implant tube 
was verified by irrigation with balanced salt solution. The 
implant was then anchored 8-10 mm posterior to the lim-
bus between the rectus muscles. A vitrectomy was done 
using a 23-gauge vitreous cutter driven by a vitrectomy 
unit and a DORC two-step system (Dutch Ophthalmic 
Research Company, Exeter, NH, USA). A sclerotomy was 
placed 3.5 mm posterior to the limbus in all eyes (Fig. 1A). 
Full panretinal endolaser photocoagulation also was ap-
plied if necessary. After the priming of the tube using 1 ml 
of balanced salt solution, the implant tube was trimmed to 
a length of 3-4 mm past the neighboring sclerotomy site. 
Next, the tube was inserted through the cutter probe scle-
rotomy site and anchored to episclera with 9-0 nylon (Fig. 
1B). The implant entry site was covered by a heterologous 
scleral patch graft. Following removal of the remaining 
sclerotomy sites, cannula wounds were carefully inspected. 
Whenever there was wound leakage or a decrease in IOP, 
a releasable suture was applied with 8-0 nylon followed by 
closure of the conjunctiva and tenon’s capsule. Finally, 10 
mg of tobramycin and 1.2 mg of dexamethasone were in-
jected subconjunctivally away from the implant position. 
Results 
The underlying pathologies were proliferative diabetic 
retinopathy in all cases. All the patients received at least 6 
months of follow-up care. Preoperative laser therapy was 
not possible due to vitreous hemorrhage or opacity. The 
angle was able to be checked in only six eyes; they were 
closed with neovascularization or peripheral anterior syn-
echia. Baseline patient and clinical characteristics are sum-
marized in Table 1. 
The mean age of eleven patients (6 male, 5 female) was 
51.3 ± 8.8 years (range, 39 to 66 years). The mean follow-
up was 12.2 months (range, 8 to 25 months). Eight patients 
had a previous panretinal photocoagulation (PRP) and 
seven patients had a previous vitrectomy. Preoperative lens 
status was pseudophakic in eight eyes and phakic with 
cataract formation in two eyes which underwent combined 
phacoemulsification with intraocular lens implantation. 
All cases showed significantly improved postoperative 
IOP. The mean preoperative IOP was 35.9 ± 6.3 mmHg and 
the average postoperative IOP at the last visit was 13.3 ± 
3.2 mmHg. Fig. 2 shows the profile of IOP change within 
all patients. Even though control of IOP (8 to 18 mmHg) 
A B
Fig. 1. (A) Intraoperative photograph shows a 23-gauge sclerotomy 3.5 mm posterior to the limbus, and (B) Ahmed valve tube inserted 
through the cutter probe sclerotomy site and anchored to episclera with 9-0 nylon.94
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Fig. 2. Preoperative (Preop) and postoperative intraocular pres-
sure (IOP) changes in all patients.
Table 1. Preoperative and postoperative clinical findings with patient information
No. Sex/
age Eye PRP 
history
Avastin 
history
Previous 
ocular surgery
Preoperative Postoperative (last F/U)
BCVA IOP 
(mmHg)
No. of 
Meds BCVA IOP 
(mmHg)
No. of 
Meds
F/U 
mon Complication
1  M / 48 Left O O IOL FC 32 2 0.80 12 1 25 VH
2   F / 49 Right O O PPV, IOL 0.10 34 3 0.30 14 1 16 Transitory hypotony
3   F / 66 Left O O PPV, IOL 0.10 34 3 0.40 08 0 13 -
4  M / 42 Right O O PPV, IOL LP 45 3 HM 16 2 12 -
5   F / 54 Right O X PPV, IOL 0.02 50 3 0.10 10 1 12 VH, transient hypertension
6  M / 64 Left X O None LP 32 3 HM 12 1 11 -
7  M / 52 Left O O PPV, IOL 0.30 35 3 0.40 17 1 10 -
8   F / 56 Left O O PPV, IOL HM 30 3 0.08 12 1 10 -
9  M / 39 Left X X None HM 35 3 FC 11 1 09 -
10   F / 41 Left O O PPV, IOL HM 30 3 0.15 16 2 09 Microscopic hyphema
11  M / 53 Right X O None HM 38 3 0.30 18 2 08 Transient hypertension
PRP = panretinal photocoagulation; BCVA = best-corrected visual acuity; IOP = intraocular pressure; Meds = glaucoma medications; F/U 
= follow-up; IOL=Intraocular lens; FC = finger counting; VH = vitreous hemorrhage; PPV = pars plana vitrectomy; LP = light perception; 
HM = hand motions.
was achieved in all patients, 10 of 11 patients still needed 
antiglaucoma medication (mean number of medications, 
1.2 ± 0.6). The number of topical antiglaucoma medication, 
however, was reduced from the preoperative 2.9 ± 0.3. 
All eleven eyes showed favorable visual acuity with the 
improvement of mean logarithmically to the minimum 
angle of resolution visual acuity from preoperative 1.67 ± 
0.61 to postoperative 0.96 ± 0.67. In one case (patient num-
ber 9), conventional Ahmed valve implantation into the 
anterior chamber was also performed in the fellow eye be-
cause of the same condition in the left eye, which showed 
an unsatisfactory outcome with the improvement of IOP 
from 32 mmHg preoperatively to 26 mmHg at final follow 
up despite using two topical antiglaucoma medications.
No unmanageable intraoperative or postoperative com-
plications developed in this series. A transient hypotony 
occurred at the first postoperative day in only one eye, 
which recovered spontaneously. In addition, hyperten-
sive phase occurred in two eyes postoperatively, which 
responded to the topical antiglaucoma medication. Two 
eyes of postoperative vitreous hemorrhage and one eye of 
microscopic hyphema were encountered, but they were 
stabilized and resolved without any management.
Discussion
NVG is the final complication of PDR. The incidence of 
NVG in PDR has significantly declied during the last 10 
years due to the improvement in management of diabetic 
patients and systematic panretinal photocoagulation. How-
ever, NVG in PDR classically carries a poor prognosis, 
typically resulting in severe loss of vision [1].
PRP remains the first-line of therapy for NVG. Second-
arily, a filtering procedure associated with antimetabolites 
or an anterior chamber drainage implant may be used 
individually if necessary. Bevacizumab has been reported 
to lead to the regression of neovascularization in eyes with 
PDR and NVG [14,15]. 
Drainage devices have improved the management of 
refractory NVG. Variable success rates for IOP control 
have been reported ranging from 47% to 96% for Ahmed 
implant in patients with NVG [16,17]. Typically, drainage 
tube is implanted through the corneal limbus into anterior 
chamber. However, in some cases, such as corneal disease 
and significant neovascularization of the anterior segment, 
it can be placed through the pars plana into the vitreous 
cavity.  
A drainage implant combined with pars plana vitrec-
tomy has several advantages in PDR patients with uncon-
trolled IOP. First, media opacities such as vitreous hemor-
rhage and vitreous opacity may be cleared, facilitating 
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fundus evaluation in the early postoperative period. Sec-
ond, NVG and PDR may be treated during a single opera-
tion. Intraoperative endolaser photocoagulation is helpful 
in inducing regression of iris neovascularization. Third, 
pars plana placement of a drainage implant decreases the 
chance of endothelial touch and hyphema [18]. However, 
possible posterior segment complications associated with 
this combined approach include retinal detachment, tube 
obstruction by vitreous and placement of the tube into the 
suprachoroidal or subretinal space [18,19]. The advantage 
of placing the tube into the anterior chamber is that the 
tube can be visualized directly and tube obstruction can 
be diagnosed readily [18]. Thus, the decision as to which 
drainage implant is better when combined with pars plana 
vitrectomy must be based on the individual clinical situa-
tion. In the case of refractory glaucoma with poor anterior 
chamber condition and vitreoretinopathy, the pars plana 
implant combined with vitrectomy is usually recommend-
ed. In our experience, we prefer the pars plana drainage 
implant combined with vitrectomy for all refractory NVG 
in PDR patients regardless of the anterior chamber. We be-
lieve that the final visual acuity of the disease is influenced 
by the progression of the diabetic retinopathy as well IOP.
The vitreous hemorrhage and various cytokines includ-
ing vascular endothelial growth factor are the main factors 
associated with the progression of diabetic retinopathy. 
We hypothesize that pars plana implant may play a role in 
carrying those factors out of vitreous cavity as well aque-
ous. Therefore, we propose the drainage implant through 
the pars plana in PDR with NVG is more effective than 
the implant of valve through the anterior chamber in PDR 
progression. In our study, two cases of postoperative vitre-
ous hemorrhages were developed but disappeared within 2 
weeks, which is faster than usual. To our knowledge, there 
are no comparative studies between the anterior chamber 
and pars plana implant until now.
The complications that occur with implants through 
anterior chamber include extrusion of the drainage tube, 
conjunctival erosion with exposure tube, and iritis. Our 
study did not show any complication associated with tube 
extrusion, which suggests that the implantation of Ahmed 
valves through the pars plana can decrease such complica-
tions. 
We had two hypertensive phases among the 11 cases, 
which responded to topical medication. In comparison 
to previous reported rates of 82% [20] and 40% [21], our 
results indicate a reduced risk of ocular hypertension, and 
suggest that the combination of 23-gauge pars plana vit-
rectomy and Ahmed valve implantation is a better surgical 
approach in eyes with NVG and coexisting vitreoretinal 
problem such as PDR.
At present, small gauge sutureless vitrectomy is more 
prevalent than 20-gauge vitrectomy. Pars plana implant 
could also be applied in small gauge vitrectomy. Recchia 
et al. [22] first described the technique of small gauge (23 
or 25 gauge) vitrectomy combined with glaucoma drain-
age implant. In that report, primary placement of the tube 
into the posterior segment was performed in cases of angle 
closure or corneal endothelial decompensation and was 
successful in lowering IOP in the majority of patients. 
Here, we report the outcome of pars plana Ahmed valve 
implantation combined with 23-gauge vitrectomy in 11 
consecutive patients with NVG in PDR. Our experience 
suggests that the 23-gauge vitrectomy is suitable for pars 
plana implant because the valve size fits the 23-gauge scle-
rotomy site. 
To our knowledge, an immediate postoperative hypotony 
may result if the sclerotomy is not closed tightly. The tube 
lumen of the Ahmed valve fits the 23-gauge needle, which 
results in no aqueous leakage without additional sutures. It 
is comparable to the 20-gauge system, which has been as-
sociated with an increased risk of postoperative hypotony 
due to leakage through the incision site [23]. In our study, 
hypotony-associated complications occurred in only one 
case (case 2), which was transitory and may be the cause of 
leakage in the other sutureless incision site. After that, we 
used a releasable suture in three cases of wound leakage 
expected in the other slcerotomy site except tube implant 
site.  
The well-known advantages of small gauge vitrectomy 
such as 23-gauge or 25-gauge over 20-gauge vitrectomy 
include faster tissue and wound healing, less inflammation, 
and less patient discomfort [24]. With 23-gauge vitrectomy 
and pars plana implant surgery compared to the 20 gauge 
procedure, we also believe that shorter surgery time, faster 
wound healing, conjunctival preservation, and more pa-
tient comfort are convincing factors for its adoption. 
In this combined procedure, complete removal of the 
vitreous at the site of implant is crucial to the success in 
pars plana implant surgery. For this, we shaved the vitre-
ous base of the cutter site pressing with a depressor. After 
insertion of the tube through the incision site, we identified 
the tube tip location in the inner vitreous cavity. In our 
cases, there is no vitreous strand obstruction. 
Presently, all patients showed improved visual acuity 
and achieved a postoperative IOP between 8 mmHg and 
18 mmHg. But 10 of 11 cases still required antiglaucoma 
medication with at least 1 topical treatment, whose intend-
ed usage was to decrease IOP as much as possible because 
eight of eleven patients were in a last eye state (the other 
eye is blind). 
Even given the small case number, these results are 
notably consistent compared with previous studies. Due 
to the small sample size of this study and possible incom-
parability of cases, it is difficult to conclude the superior-
ity of Ahmed valve implantation into the vitreous cavity 
combined with 23-gauge vitrectomy. But it is noteworthy 
that stable and satisfactory results were obtained using 96
Korean J Ophthalmol Vol.26, No.2, 2012
23-gauge and not 23-gauge. No serious postoperative com-
plications were noted in any of the 11 patients during the 
follow-up period. 
Limitations of the current series include its retrospective 
nature, lack of a control series, small sample size, and lim-
ited follow-up period. A direct case-controlled comparison 
of these procedures and further prospective randomized 
trials with a longer follow-up will be required to establish 
the superiority of Ahmed valve implantation combined 
with 23-gauge pars plana vitrectomy.
In conclusion, the combination of 23-gauge vitrectomy 
and pars plana Ahmed valve implantation can be an ef-
fective and safe surgery in PDR patients with refractory 
NVG.
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